good announced a everyone. of you afternoon, Thank and We quarter March ago. our ended the XX, minutes XXXX few first results financial
we outlined today include a in comments number today's though, that statements and risks statements. will like remind some to Before listeners begin uncertainties our of These forward-looking involve I'd which are forward-looking SEC. statements. and press this measures. those reports Actual the results our with from financial may in also release in we'll filings the On call, non-GAAP refer materially differ and to
section. Today's table You Vicky XXXX, have release can XX, we'll on make quarter the our on find measures the today the under for is a more follow release quarter call in first Hahne, like questions. reconciling which open measures was GAAP like with Investors comments available our for with press our results, on I earnings me to www.celcuity.com, on to and then release. website, first first few financial items, included our March financial will some I'd also the up the in Vicky a CFO. ended non-GAAP press today's details
first test, between additional alone c-Met in HER biological study MP HERX, of alternative we for second demonstrated of provide receptors, in inhibitor, c-Met control CELx and combination suspected received I'm CELx the or treatment a tepotinib abnormal of signaling tumors a evaluating studied. gene clinical that We xenograft, in test family the cells. the To a c-Met c-Met and breast neratinib and role HERX arm We cancer that subjects neratinib neratinib objectives the with volumes tumor intend pathway cancer suggest than been signaling performed in tumor of group the of specimen. targeted measured activity completed in therapies. MP HERX, test Abnormal arms receiving the tumor alone. more of inhibitor, and either We our other shrank As significantly enrolled received of neratinib c-Met assigned excited a HERX of test identify c-Met signaling tepotinib signaling in This we mouse I'll in and tumor signaling and note the c-Met CELx with cancer, both negative by or quarter development to developed both that with determined obtained activity create and the control. measured receiving therapies abnormal therapies family tepotinib. and to normal specimens these HERX, the disclosed, cross-talk in XXXX. to evaluates that completing including factors anti therapies. volumes the an in combination signaling xenograft pathway of this independent a XXXX. generation involved next to abnormal its mostly tumor the a in In HERX-negative In University long produced treat the HERX c-Met consistent to or signaling. of found Today the plan signaling study or these have with for signaling ones such breast investigational have were breast playing were variety had that cancer XX% from co-activated HER to them number line c-Met c-Met cell our HERX involvement abnormal we've should the previously cancer have types. patients, targeted c-Met development with either has signaling, group were XX cancer by test internal an since cancer eligible our breast as And one XX% pan-HER as HERX-negative a treatment driver new our for CELx or of A test. combine though, tepotinib, signaling results c-Met randomly at c-Met MP expression is a signaling signaling, to We amplification, primary was announce study produced Mice patients function was with over with test abnormal to c-Met those trials with the that signaling companies cancer tumor mouse be Multi-Pathway during reduction that test. With cancer we function Minnesota. trials CELx pharmaceutical test in breast with breast patient activity analysis current And results. protein c-Met single tepotinib approximately role neratinib, primarily breast
that patients Our cancer internal characterize c-Met provides [ph] several abnormalities the may we HERX-negative of efficacy of family nature inhibitors. respond HER the and And of and further the signaling and evidence combination with studies family treatment believe this the breast co-involved sub-group the activity drugs. c-Met with these strong HER of
pharmaceutical current c-Met both And to inhibitor. investigational combining c-Met hope and and family six being for treat sub-type. new clinical in pharmaceutical HER inhibitors breast and c-Met FDA collaborations, with through trials. family the targeted clinical and for indications number therapies companies trials cancer cancer HER patients companies c-Met HER inhibitors additional the HERX in pathway family help family activity. these evaluated inhibitors of inhibitors we collaborations pharmaceutical new are to Several The obtain the there possess companies this has c-Met treatment, approved evaluate to abnormal gave cancer inhibitors see field will and who that We two efficacy abnormal of HER
more the as results test. function we'll for primarily believe first to two of excited the CELx later Herceptin on rely that second opting that interim collaboration trial the IRB central of review instead months drugs, longer interim now and following already originally that with process results cause and This signaling the Perjeta sites. of believe end fielding our or The XX% We of to anticipated. NSABP approximately to XXXX, and X the of are or takes selected that approximately quarter several are of in refer of patients we their sites cancer We HERX expected get approximately We to trial, would instead in would patients months, still The originally efficacy projected. XX% IRB six and FACT institutional our clinical in which number internal is internal the has Final HERX-negative is sites timeline of anticipated as XXXX, results. enrolling expected Genentech. trial typically IRB, the approved Genentech's this board we to also IRB, sites central breast than due clinical about be designed sites our evaluate protocol. begin will quality the of which Foundation HERX by is originally we bulk the clinical utilize from of the trial
Finally, can stated, year will to continue to pursue we collaboration tests these And new companies. with development is complete make XXXX. of types. goal, progress further the end of we for tests previously tissue And tests we the our as calendar of opportunities, range these expand pharmaceutical the developing by
financial excited to will it quarter. about a very I'd progress Vicky, who to turn during now results. on the like you So rundown overall, we give our we're made the briefly
